CAMBRIDGE, Mass., May 4, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management will be participating in two panel discussions at the Biotechnology International Organization (BIO) International Convention at the Boston Convention & Exhibition Center.
Steven H. Holtzman, Chair and Chief Executive Officer, will be moderating a panel discussion in the Business Development track titled "Making the Perfect Match: Successful Marriages in Strategic Alliances." The panel will take place on Monday, May 7, 2007 in Room 206 AB from 11:00 a.m. - 12:30 p.m. EDT.
Adelene Q. Perkins, Executive Vice President and Chief Business Officer, will be participating in a panel discussion in the Finance Track titled "Funding vs. Value Retention: Can a small company do both?" moderated by Roger Longman of Windhover Information Inc. The panel will take place on Tuesday, May 8, 2007 in Room 204 AB from 4:00 - 5:30 p.m. EDT.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients first-in-class or best-in-class medicines for the treatment of cancer and related conditions. For more information on Infinity, please refer to the company's website at http://www.ipi.com.
INFI-G